According to the rating "TechUp-2014" GEROPHARM, Group of Companies, entered the TOP-30 high-tech fast developing Russian companies.
Rating "TechUp" was first initiated by the Russian Venture Company (RVC) in partnership with the Association of Innovative Regions of Russia (AIRR) with the support of Rosnano and the Fund for Assistance in 2012. In 2013, PwC joined the development of the rating as a project partner; SME Bank became a partner of the rating in 2014.
The rating determines the leaders in the segment of medium-sized businesses able to play a key role in the development and modernisation of the Russian technology industries in the future. The study results highlight the main characteristics of the high-tech fast-growing companies that distinguish them from the companies whose business does not have a technological component.
This year, more than 110 application forms to participate in the rating were submitted among which 80 passed the qualifying criteria. The nominees assessment board comprised of 26 experts. The companies which entered the Top-50 of the "TechUp" rating represented 19 subjects of the Russian Federation. Most of these companies are located in the Central (46%), Volga (24%) and North-West (18%) federal districts. The rating included companies operating in 6 different technological sectors, including pharmaceutics, biotechnology and medical equipment, which amounted to 16%; the most ranking sector was mechanical engineering, instrument and electric engineering (36%), information and communication technologies (20%), and materials and construction (12%). GEROPHARM, whose dynamic innovative development was noted by experts for the third time, joined the Top-30 rating in 2014.
For GEROPHARM, Group of Companies, 2013 was the year of significant investments in business development: expansion and commissioning of new capacities, launching the production of new medicines, as well as new projects in the field of scientific research and development (R&D).
Following the concept of integrated development, GEROPHARM pays great attention to the creation of modern innovative infrastructure. In 2013, GEROPHARM completed a major project in the Moscow Region on the construction of Russia’s first manufacture of genetically engineered human insulin on the basis of a full cycle: starting from the substance biosyntheses up to the ready dosage form. In 2013–2014 the project's design capacity was achieved; the new technologies were tested and scaled. Currently, the plant capacities allow to meet 20% of Russia's demand for insulin.
An important aspect of GEROPHARM is its scientific research and development activity. Projects for the development of medical products, especially through biotechnology, are long-term, as they require numerous studies, and are characterized by significant financial investment and long payback period. In 2013, GEROPHARM launched Levetinol® for the treatment of epilepsy and initiated a number of new directions for research. There are currently more than 15 projects at various stages of development, among them three projects are conducted under federal target programs of the Ministry of Industry and Trade of the Russian Federation and the Ministry of the Education of the Russian Federation, including the development of the rapid-acting (Lispro) and long-acting (Glargine) analogue insulins; the company plans to create its own producing strain and production technology.